# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001829126-25-001180
Filing Date
2025-02-24
Accepted
2025-02-24 08:31:01
Documents
17
Period of Report
2025-02-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | cyclacel_8k.htm iXBRL | 8-K | 30695
2 | EXHIBIT 10.1 | cyclacel_10-1.htm | EX-10.1 | 6259
3 | GRAPHIC | ex10-1_001.jpg | GRAPHIC | 779399
4 | GRAPHIC | ex10-1_002.jpg | GRAPHIC | 427268
| Complete submission text file | 0001829126-25-001180.txt |  | 1838957

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL SCHEMA FILE | cycc-20250220.xsd | EX-101.SCH | 3744
6 | XBRL DEFINITION FILE | cycc-20250220_def.xml | EX-101.DEF | 26582
7 | XBRL LABEL FILE | cycc-20250220_lab.xml | EX-101.LAB | 36614
8 | XBRL PRESENTATION FILE | cycc-20250220_pre.xml | EX-101.PRE | 25206
19 | EXTRACTED XBRL INSTANCE DOCUMENT | cyclacel_8k_htm.xml | XML | 5625

Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 25654337
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)